UK’s F-star signs new deal with Merck
Cambridge, UK-based F-star has signed a new collaboration with Merck under which the drug giant has the option to develop and commercialise five of its bispecific immuno-oncology antibodies.
Read More
Tag: F-star
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
